ADARx Pharmaceuticals targets $1.74 billion valuation in US IPO

Drug developer ADARx seeks $1.74 billion valuation in US IPO

ADARx Pharmaceuticals targets $1.74 billion valuation in US IPO

Sept 21 (Reuters) - ADARx Pharmaceuticals is seeking a valuation of up to $1.74 billion in ​its U.S. initial public ‌offering, the company said on Monday, as investor appetite for biotech listings strengthens. The San Diego, California -based company ‌...

ADARx Pharmaceuticals San Diego IPO Targets $1.74 Billion

San Diego biotech ADARx seeks up to $371.9 million in a Nasdaq IPO, with AbbVie investing up to $100 million alongside it.

ADARx targets $319M IPO as TRexBio, Retension join filing queue

The fall IPO train is boarding. ADARx Pharmaceuticals, a well-funded siRNA biotech in Phase 3, plans to raise about $318 million in its proposed initial public offering, according to its